Enovis Corporation (ENOV) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ENOV SEC filings page.
Enovis Corporation (ENOV) reported $2.2B in revenue for fiscal year 2025, up 6.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Enovis is growing sales with improving gross margins, but heavy non-cash charges and reinvestment leave reported profitability and free cash flow near zero.
In FY2025, EBITDA of$219.9M sat beneath depreciation and amortization of$1.34B , so the operating loss was driven chiefly by the accounting burden of accumulated assets, not gross-profit erosion. Operating cash flow of$217M was nearly consumed by capital spending, leaving free cash flow close to zero; this makes the accounting loss look harsher than cash operations, but shows little cash left after reinvestment.
Gross margin improved from
Total assets fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Enovis Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Enovis Corporation has an operating margin of -50.0%, meaning the company loses $50 on every $100 of revenue. This results in a profitability score of 16/100. This is down from -36.8% the prior year.
Enovis Corporation's revenue grew 6.7% year-over-year to $2.2B, a solid pace of expansion. This earns a growth score of 75/100.
Enovis Corporation has elevated debt relative to equity (D/E of 0.85), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 10/100, reflecting increased financial risk.
Enovis Corporation's current ratio of 2.02 indicates adequate short-term liquidity, earning a score of 59/100. The company can meet its near-term obligations, though with limited headroom.
While Enovis Corporation generated $217.3M in operating cash flow, capex of $197.4M consumed most of it, leaving $19.9M in free cash flow. This results in a low score of 25/100, reflecting heavy capital investment rather than weak cash generation.
Enovis Corporation posts a -79.5% return on equity (ROE), meaning it loses $80 for every $100 of shareholders' equity. This results in a returns score of 16/100. This is down from -32.2% the prior year.
Enovis Corporation scores -0.45, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.1B) relative to total liabilities ($2.3B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Enovis Corporation passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Enovis Corporation reported a net loss of $1.2B while generating $217.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Enovis Corporation reported an operating loss of $1.1B against $34.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Enovis Corporation generated $582.8M in revenue in Q3 2026. This represents an increase of 3.2% from the same quarter a year earlier. Against the prior quarter it is down 1.1%.
Enovis Corporation's EBITDA was $88.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 61.5% from the same quarter a year earlier. Against the prior quarter it is up 10.7%.
Enovis Corporation reported -$1.2M in net income in Q3 2026. This represents an increase of 96.8% from the same quarter a year earlier. Against the prior quarter it is up 86.4%.
Enovis Corporation earned -$0.02 per diluted share (EPS) in Q3 2026. This represents an increase of 96.9% from the same quarter a year earlier. Against the prior quarter it is up 86.7%.
Cash & Balance Sheet
Enovis Corporation generated $31.1M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 815.8% from the same quarter a year earlier. Against the prior quarter it is up 207.9%.
Enovis Corporation held $12.6M in cash against $1.2B in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Enovis Corporation's gross margin was 61.6% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.4 percentage points.
Enovis Corporation's operating margin was 3.0% in Q3 2026, reflecting core business profitability. This is up 6.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.9 percentage points.
Enovis Corporation's net profit margin was -0.2% in Q3 2026, showing the share of revenue converted to profit. This is up 6.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.3 percentage points.
Enovis Corporation's ROE was -0.1% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is up 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.
Capital Allocation
Enovis Corporation invested $31.7M in research and development in Q3 2026. This represents an increase of 3.2% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.
Enovis Corporation invested $43.9M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 1.1% from the same quarter a year earlier. Against the prior quarter it is down 16.9%.
Not reported for Q3 2026.
ENOV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $582.8M+3.2% | $589.2M+5.4% | $548.9M-2.2% | $564.5M+11.7% | $558.8M+6.4% | $561.0M+23.3% | $505.2M+21.0% | $525.2M+22.6% |
| Cost of Revenue | $223.5M-2.7% | $223.7M-1.3% | $220.0M-13.2% | $229.8M+5.1% | $226.6M-4.1% | $253.5M+33.0% | $218.8M+25.3% | $236.3M+31.2% |
| Gross Profit | $359.2M+7.3% | $365.5M+10.0% | $328.9M+7.0% | $334.7M+16.8% | $332.2M+15.0% | $307.5M+16.3% | $286.5M+17.9% | $288.9M+16.3% |
| R&D Expenses | $31.7M+3.2% | $31.5M+10.5% | $29.7M+24.2% | $30.7M+49.8% | $28.5M+21.5% | $24.0M+30.7% | $20.5M+3.0% | $23.5M+24.1% |
| SG&A Expenses | $263.7M-1.3% | $282.8M+5.1% | $263.6M+2.3% | $267.1M+6.9% | $269.0M+1.9% | $257.7M+22.1% | $249.9M+22.3% | $264.1M+27.0% |
| Operating Income | $17.4M+203.7% | $6.5M+114.0% | -$558.5M+16.0% | -$16.8M+47.1% | -$46.8M-5.8% | -$664.7M-11450.8% | -$31.7M-54.9% | -$44.2M-205.1% |
| EBITDA | $88.4M+61.5% | $79.9M+223.9% | -$484.1M-1018.8% | $54.8M+38.7% | $24.7M+14.5% | $52.7M+3.6% | $39.5M+12.9% | $21.5M-74.0% |
| Interest Expense | $8.0M-13.5% | $9.2M-0.2% | $8.8M-2.7% | $9.3M-16.0% | $9.2M-45.9% | $9.1M+113.2% | $11.1M+91.9% | $17.0M+316.3% |
| Income Tax | $8.5M-21.3% | $9.0M+611.3% | $4.0M-86.6% | $10.8M+218.7% | -$1.8M+80.1% | $29.9M+551.6% | -$9.1M-50.3% | -$8.9M-89.0% |
| Net Income | -$1.2M+96.8% | -$8.8M+84.3% | -$571.1M+18.8% | -$36.7M-16.6% | -$56.0M-200.3% | -$703.3M-23829.3% | -$31.5M-994.5% | -$18.6M-86.5% |
| EPS (Basic) | -$0.02+96.9% | -$0.15+84.7% | -$9.99+21.3% | -$0.64-10.3% | -$0.98-188.2% | -$12.70-21266.7% | -$0.58-1060.0% | -$0.34-88.9% |
| EPS (Diluted) | -$0.02+96.9% | -$0.15+84.7% | -$9.99+21.3% | -$0.64-10.3% | -$0.98-188.2% | -$12.70-21266.7% | -$0.58-1060.0% | -$0.34-88.9% |
| Diluted Shares (Avg) | 58M+0.8% | 57M+0.9% | 57M | 57M+2.6% | 57M+3.5% | N/A | 56M+2.0% | 55M+0.6% |
ENOV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.8B-25.0% | $3.8B-21.4% | $4.4B-6.0% | $5.0B-9.5% | $4.9B-10.4% | $4.7B+4.6% | $5.6B+26.1% | $5.4B+22.5% |
| Current Assets | $1.2B-5.1% | $1.2B+1.8% | $1.3B+11.7% | $1.3B+6.4% | $1.2B+3.9% | $1.1B+27.9% | $1.2B+40.8% | $1.2B+32.2% |
| Cash & Equivalents | $12.6M-71.5% | $33.1M-13.9% | $33.6M-30.2% | $44.1M+24.4% | $38.5M+9.9% | $48.2M+33.1% | $35.4M+10.3% | $35.0M+7.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $601.7M-4.2% | $602.5M+2.8% | $613.8M+12.2% | $628.2M+3.0% | $585.9M-4.7% | $547.1M+16.7% | $609.7M+29.5% | $615.0M+35.5% |
| Accounts Receivable | $441.8M-2.6% | $444.2M+2.0% | $431.8M+6.1% | $453.7M+13.4% | $435.6M+10.4% | $407.0M+39.6% | $400.2M+44.5% | $394.7M+32.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $709.9M-60.2% | $711.9M-58.9% | $1.2B-28.0% | $1.8B-25.6% | $1.7B-26.3% | $1.7B-17.9% | $2.4B+18.1% | $2.4B+15.7% |
| Total Liabilities | $2.3B-6.3% | $2.4B+4.3% | $2.4B+11.8% | $2.4B+10.1% | $2.3B+4.7% | $2.2B+97.9% | $2.2B+131.1% | $2.2B+116.9% |
| Current Liabilities | $612.1M+7.7% | $608.7M+27.5% | $575.4M+8.8% | $568.2M+7.2% | $477.4M-7.8% | $529.0M+43.1% | $530.2M+49.2% | $518.0M+46.5% |
| Non-Current Liabilities | $1.7B-10.5% | $1.7B-1.9% | $1.8B+12.8% | $1.9B+11.0% | $1.8B+8.7% | $1.6B+126.1% | $1.7B+179.3% | $1.6B+155.8% |
| Long-Term Debt | $1.2B-9.2% | $1.3B-5.6% | $1.3B+2.3% | $1.4B+3.6% | $1.4B+2.9% | $1.3B+180.9% | $1.3B+235.6% | $1.3B+232.4% |
| Total Equity | $1.5B-42.7% | $1.5B-43.6% | $2.0B-21.1% | $2.6B-22.6% | $2.6B-20.3% | $2.6B-25.0% | $3.3B-3.2% | $3.3B-4.7% |
| Retained Earnings | -$1.5B-293.2% | -$1.5B-335.5% | -$946.9M-234.6% | -$375.7M-189.4% | -$339.0M-175.0% | -$283.0M-152.2% | $420.3M-22.1% | $451.8M-16.7% |
ENOV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $75.0M+57.1% | $24.0M+1600.7% | $82.6M-6.5% | $47.8M-10.8% | -$1.6M-120.5% | $88.3M+29.1% | $53.6M+72.7% | $7.8M-72.3% |
| Depreciation & Amortization | $71.0M-0.7% | $73.4M+2.7% | $74.4M-89.6% | $71.6M+0.5% | $71.4M+8.6% | $717.4M+1167.2% | $71.2M+28.4% | $65.8M-32.5% |
| Stock-Based Compensation | $8.9M+2.7% | $8.8M+18.1% | $9.0M | $8.7M+10.7% | $7.4M-3.1% | N/A | $7.8M-6.4% | $7.6M-13.8% |
| Capital Expenditures | $43.9M-1.1% | $52.8M+22.1% | $53.5M+0.6% | $44.4M-13.3% | $43.3M+9.8% | $53.2M+90.4% | $51.2M+89.4% | $39.4M+7.1% |
| Free Cash Flow | $31.1M+815.8% | -$28.9M+35.7% | $29.1M-17.2% | $3.4M+43.6% | -$44.9M-41.8% | $35.1M-13.2% | $2.4M-40.5% | -$31.6M-263.5% |
| Investing Cash Flow | -$45.0M+9.6% | -$53.1M+12.3% | -$56.1M+3.2% | -$49.8M+14.8% | -$60.5M-46.4% | -$57.9M+2.5% | -$58.4M-241.5% | -$41.3M+68.6% |
| Financing Cash Flow | -$50.6M-911.5% | $26.0M-49.2% | -$36.9M-83.8% | $6.2M+4310.1% | $51.2M+1940.3% | -$20.1M-820.0% | -$148K+98.9% | $2.5M-97.8% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ENOV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.6%+2.3pp | 62.0%+2.6pp | 59.9%+5.1pp | 59.3%+2.6pp | 59.5%+4.4pp | 54.8%-3.3pp | 56.7%-1.5pp | 55.0%-2.9pp |
| Operating Margin | 3.0%+6.0pp | 1.1%+9.5pp | -101.7% | -3.0%+3.3pp | -8.4%+0.1pp | -118.5% | -6.3%-1.4pp | -8.4%-5.0pp |
| Net Margin | -0.2%+6.3pp | -1.5%+8.5pp | -104.0% | -6.5%-0.3pp | -10.0%-6.5pp | -125.4% | -6.2%-5.5pp | -3.5%-1.2pp |
| Return on Equity | -0.1%+1.3pp | -0.6%+1.6pp | -28.3%-0.8pp | -1.4%-0.5pp | -2.1%-1.6pp | -27.4%-27.5pp | -0.9%-0.9pp | -0.6%-0.3pp |
| Return on Assets | 0.0%+0.7pp | -0.2%+0.9pp | -12.9%+2.0pp | -0.7%-0.2pp | -1.1%-0.8pp | -14.9%-15.0pp | -0.6%-0.5pp | -0.3%-0.1pp |
| Current Ratio | 1.98-0.3x | 2.04-0.5x | 2.22+0.1x | 2.250.0x | 2.55+0.3x | 2.17-0.3x | 2.27-0.1x | 2.26-0.2x |
| Debt-to-Equity | 0.84+0.3x | 0.87+0.4x | 0.66+0.2x | 0.53+0.1x | 0.52+0.1x | 0.51+0.4x | 0.40+0.3x | 0.40+0.3x |
| Asset Turnover | 0.150.0x | 0.150.0x | 0.120.0x | 0.110.0x | 0.110.0x | 0.120.0x | 0.090.0x | 0.100.0x |
| FCF Margin | 5.3%+4.7pp | -4.9%+3.1pp | 5.3%-1.0pp | 0.6%+0.1pp | -8.0%-2.0pp | 6.3%-2.6pp | 0.5%-0.5pp | -6.0%-4.0pp |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Enovis Corporation ENOV | FY2025 | $2.2B | -$1.2B | -52.7% | $1.1B | 34/100 |
| Artivion, Inc. AORT | FY2025 | $441.3M | $9.8M | 2.2% | $1.1B | 49/100 |
| CONMED Corporation CNMD | FY2025 | $1.4B | $47.1M | 3.4% | $1.4B | 53/100 |
| UFP Technologies Inc UFPT | FY2025 | $602.8M | $68.3M | 11.3% | $2.3B | 72/100 |
| NovoCure Limited NVCR | FY2025 | $655.4M | -$136.2M | -20.8% | $1.7B | 63/100 |
| Integra LifeSciences Holdings IART | FY2025 | $1.6B | -$516.8M | -31.6% | $1.1B | 37/100 |
Where Enovis Corporation Ranks
Frequently Asked Questions
What is Enovis Corporation's annual revenue?
Enovis Corporation (ENOV) reported $2.2B in total revenue for fiscal year 2025. This represents a 6.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Enovis Corporation's revenue growing?
Enovis Corporation (ENOV) revenue grew by 6.7% year-over-year, from $2.1B to $2.2B in fiscal year 2025.
Is Enovis Corporation profitable?
No, Enovis Corporation (ENOV) reported a net income of -$1.2B in fiscal year 2025, with a net profit margin of -52.7%.
What is Enovis Corporation's EBITDA?
Enovis Corporation (ENOV) had EBITDA of $219.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Enovis Corporation have?
As of fiscal year 2025, Enovis Corporation (ENOV) had $36.4M in cash and equivalents against $1.3B in long-term debt.
What is Enovis Corporation's gross margin?
Enovis Corporation (ENOV) had a gross margin of 59.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Enovis Corporation's operating margin?
Enovis Corporation (ENOV) had an operating margin of -50.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Enovis Corporation's net profit margin?
Enovis Corporation (ENOV) had a net profit margin of -52.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Enovis Corporation's return on equity (ROE)?
Enovis Corporation (ENOV) has a return on equity of -79.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Enovis Corporation's free cash flow?
Enovis Corporation (ENOV) generated $19.9M in free cash flow during fiscal year 2025. This represents a 129.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Enovis Corporation's operating cash flow?
Enovis Corporation (ENOV) generated $217.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Enovis Corporation's total assets?
Enovis Corporation (ENOV) had $3.8B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Enovis Corporation's capital expenditures?
Enovis Corporation (ENOV) invested $197.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Enovis Corporation spend on research and development?
Enovis Corporation (ENOV) invested $120.3M in research and development during fiscal year 2025.
What is Enovis Corporation's current ratio?
Enovis Corporation (ENOV) had a current ratio of 2.02 as of fiscal year 2025, which is generally considered healthy.
What is Enovis Corporation's debt-to-equity ratio?
Enovis Corporation (ENOV) had a debt-to-equity ratio of 0.85 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Enovis Corporation's return on assets (ROA)?
Enovis Corporation (ENOV) had a return on assets of -30.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Enovis Corporation's P/E ratio?
Enovis Corporation (ENOV) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.1B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Enovis Corporation's price-to-sales ratio?
Enovis Corporation (ENOV) trades at 0.5x sales, its market capitalization divided by revenue of $2.2B revenue, FY2025. The market capitalization is $1.1B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Enovis Corporation's Altman Z-Score?
Enovis Corporation (ENOV) has an Altman Z-Score of -0.45, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Enovis Corporation's Piotroski F-Score?
Enovis Corporation (ENOV) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Enovis Corporation's earnings high quality?
Enovis Corporation (ENOV) reported a net loss of $1.2B while generating $217.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Enovis Corporation cover its interest payments?
Enovis Corporation (ENOV) reported an operating loss of $1.1B against $34.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Enovis Corporation?
Enovis Corporation (ENOV) scores 34 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.